RBC Capital Reaffirms Their Buy Rating on Maravai Lifesciences Holdings (MRVI)
RBC Capital analyst Conor McNamara maintained a Buy rating on Maravai Lifesciences Holdings (MRVI – Research Report) on February 4 and set a ...
bovnews13h
Maravai Lifesciences Holdings Inc (MRVI) Stock Rated Neutral by Guggenheim
Notable insider trades include ORESHACK KURT, General Counsel at Maravai Lifesciences Holdings Inc (MRVI), who sold 25000 shares on Jan 31 ’25, at $5.03 each, totaling $0.13 million. On May 28 ’24, ...
TriLink BioTechnologies® and Aldevron Enter into Non-exclusive License and Supply Agreement for CleanCap® mRNA Capping Technology
TriLink BioTechnologies (TriLink®), a Maravai® LifeSciences company (NASDAQ: MRVI) and global provider of life science ...
Business Wire8d
Maravai LifeSciences Acquires Assets and Intellectual Property from Molecular Assemblies
Justin Barbosa, GM and Vice President of TriLink Discovery, added “By integrating Molecular Assemblies technology into ...
Craig-Hallum Sticks to Their Buy Rating for Maravai Lifesciences Holdings (MRVI)
In a report released today, Matt Hewitt from Craig-Hallum maintained a Buy rating on Maravai Lifesciences Holdings (MRVI – Research Report).
TriLink BioTechnologies® Partners with Avantor® to Expand Nucleic Acid Solutions in Europe
TriLink BioTechnologies (TriLink®), a Maravai® LifeSciences company (NASDAQ: MRVI) and global provider of life science ...
Yahoo Finance8d
Maravai LifeSciences Acquires Assets and Intellectual Property from Molecular Assemblies
Their team has made great strides in designing and developing an enzymatic DNA synthesis platform with exciting technical advantages over traditional chemical synthesis," said Trey Martin, CEO of ...
Nasdaq8d
Maravai LifeSciences Acquires Assets and Intellectual Property from Molecular Assemblies
CEO of Maravai LifeSciences. “We plan to further evolve and enhance Molecular Assemblies’ workflows to push the limits of oligo length and purity, and to lower costs by vertically integrating ...
Investing8d
Maravai LifeSciences expands mRNA manufacturing with new acquisition
SAN DIEGO - Maravai LifeSciences, Inc. (NASDAQ: MRVI), a $796 million market cap company known for supplying life science reagents and services, has announced the acquisition of intellectual ...